Genetesis Stock

genetesis.com/Healthcare / BioTech & PharmaFounded: 2013

Genetesis is a biopharma company focusing on the treatment of heart diseases and chest pain using digital and electric imaging technology. Genetesis has developed its Cardioflux imaging device, in which a patient can pass through, and by using magnetocardiography, it can pick up natural magnetic signals produced in the heart for optimal treatment and diagnosis options. Genetesis partners with healthcare organizations to bring its devices to the patients that could benefit from this type of cardiac care.

Register To Buy and Sell Shares

For more details on financing and valuation for Genetesis, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Genetesis’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Genetesis.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Genetesis investors also invested in these private companies

Mithril Capital Mangement
Ohio Innovation Fund
JobsOhio Growth Capital Fund
CincyTech

Team

Management Team

Peeyush Shrivastava
Co-Founder & Chief Executive Officer
Vineet Erasaia
Co-Founder & Chief Operations Officer
Emmanuel Setegn
Co-Founder & Chief Technology Officer
John Emanuel
Chief Financial Officer
Robert Takla
Chief Medical Officer

Board Members

John Rice, PhD
CincyTech
Anil Achyuta, PhD
TDK Ventures
Sajid Malhotra
Limelight Networks
Bill Baumel
Ohio Innovation Fund
Mark Cuban
Independent Director

Frequently Asked Questions About Genetesis’ Stock

plusminus
Can you buy Genetesis’ stock?
Genetesis is not publicly traded on NYSE or NASDAQ in the U.S. To buy Genetesis’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Genetesis’ stock?
Yes, you can sell stock of a private company like Genetesis. Forge can help you sell your Genetesis stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Genetesis’ stock price?
Genetesis is a privately held company and therefore does not have a public stock price. However, you may access Genetesis’ private market stock price with Forge Data.
plusminus
What is Genetesis’ stock ticker symbol?
Genetesis does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Genetesis Announces Close of $17.5 Million Series C Financing
Genetesis, the market leader in next-generation biomagnetic imaging, has announced that it has closed $17.5 million in Series C Financing. The round was led by Mithril Capital with participation from Cercano Management as well as from existing investors, including JobsOhio Growth Capital, Ohio Innovation Fund and CincyTech
Updated on: Apr 23, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.